Nakanuma Y, Tsuneyama K, Ohbu M, Katayanagi K
Department of Pathology (II), Kanazawa University School of Medicine, Japan.
Pathol Res Pract. 2001;197(2):65-76. doi: 10.1078/0344-0338-5710012.
Idiopathic portal hypertension (IPH) is characterized by a long-standing presinusoidal portal hypertension of unknown etiology in adults. Some unidentified agent(s) affect(s) the intrahepatic small portal veins or portal tracts. Immunological disturbance, thromboembolism, infectious etiology and/or increased fibrogenesis in portal tracts are suspected as being candidates for the primary agent(s). During the long clinical course of IPH, several pathological changes may occur, including subcapsular parenchymal atrophy, atrophy of the liver, portal and parenchymal fibrosis, and portal venous phlebosclerosis and thrombosis. The last-named of these lesions is mostly found in patients with a history of splenectomy. Subcapsular parenchymal and hepatic atrophy may result from a hepatocellular dropout via apoptosis or necrosis because of intrahepatic hemodynamic disturbances, particularly chronic portal venous blood insufficiency. Pericellular fibrosis and thin fibrous septa are also frequently found and associated with activated perisinusoidal cells positive for smooth muscle actin. At the same time, vague nodular hyperplasia of hepatocytes not surrounded by fibrous septa is not infrequently seen. It may resemble nodular regenerative hyperplasia, partial nodular transformation, or focal nodular hyperplasia. However, liver cirrhosis does not occur even at the terminal stage. Taking these findings into consideration, a new staging of IPH with a combination of hepatic parenchymal atrophy and portal venous thrombosis was proposed: non-atrophic liver without subcapsular parenchymal atrophy (stage I), non-atrophic liver with subcapsular parenchymal atrophy (stage II), atrophic liver with subcapsular parenchymal atrophy (stage III), and portal venous occlusive thrombosis (stage IV). IPH livers are likely to progress from stage I to stage III. Stage IV, which occurs relatively late, has a poor prognosis. This staging is applicable to clinical and autopsy cases without any histological data.
特发性门静脉高压(IPH)的特征是成人中存在病因不明的长期窦性前门静脉高压。某些不明因素影响肝内小门静脉或门静脉分支。免疫紊乱、血栓栓塞、感染病因和/或门静脉分支中纤维生成增加被怀疑是主要因素的候选者。在IPH的漫长临床过程中,可能会出现几种病理变化,包括包膜下实质萎缩、肝脏萎缩、门静脉和实质纤维化以及门静脉静脉硬化和血栓形成。这些病变中最后一种在有脾切除术史的患者中最常见。包膜下实质和肝脏萎缩可能是由于肝内血流动力学紊乱,特别是慢性门静脉血液不足,导致肝细胞通过凋亡或坏死而脱落。细胞周围纤维化和薄纤维间隔也经常出现,并与平滑肌肌动蛋白阳性的活化窦周细胞有关。同时,未被纤维间隔包围的肝细胞模糊结节性增生并不少见。它可能类似于结节性再生性增生、部分结节性转化或局灶性结节性增生。然而,即使在晚期也不会发生肝硬化。考虑到这些发现,提出了一种结合肝实质萎缩和门静脉血栓形成的IPH新分期:无包膜下实质萎缩的非萎缩性肝脏(I期)、有包膜下实质萎缩的非萎缩性肝脏(II期)、有包膜下实质萎缩的萎缩性肝脏(III期)和门静脉闭塞性血栓形成(IV期)。IPH肝脏可能从I期发展到III期。相对较晚出现的IV期预后较差。这种分期适用于没有任何组织学数据的临床和尸检病例。